 CAMBRIDGE, Mass.--BUSINESS WIRE--Epizyme, Inc. Nasdaq: EPZM, a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies today announced its Chief Executive Officer CEO succession plan, with industry veteran Grant Bogle succeeding Robert Bazemore, as President and CEO. Mr. Bazemore will move into an active consultancy role, serving as an advisor to the Company, and in particular to Mr. Bogle, for the next 12 months to ensure a smooth 